Drugs / Eltrombopag
Eltrombopag
also known as
Eltrombopag Olamine · Revolade · SB-497115-GR · EPAG · SB-497115 · Revolade (eltrombopag) · ELT · ELTR · +2 more
Small molecule targets MPL via activation
Regulatory milestones approvals, filings & regulatory actions · 8 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Filed autosomal recessive severe congenital neutropenia 2 milestones | |||||
| Filed | EU (EMA) | Revolade | autosomal recessive severe congenital neutropenia | 2014-11-12 | “Novartis submitted a Type II variation application for Revolade as a first-line SAA treatment to the European Medicines Agency in April 2018” novartis.com ↗ “Ligand Partner GlaxoSmithKline Announces EU Regulatory Submission for Severe Aplastic Anemia Indication for Revolade™” ligand.com ↗ |
| Filed | US (FDA) | Promacta | autosomal recessive severe congenital neutropenia | 2014-02-28 | “submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for Promacta™ (eltrombopag)” gsk.com ↗ “Ligand Partner GlaxoSmithKline Submits U.S. Regulatory Application for Promacta® (eltrombopag) for Severe Aplastic Anaemia” ligand.com ↗ |
| Filed chronic hepatitis C virus infection 2 milestones | |||||
| Filed | EU (EMA) | Revolade | chronic hepatitis C virus infection | 2012-05-30 | “a variation to the Marketing Authorisation Application to the European Medicines Agency for Revolade (eltrombopag) as a treatment for thrombocytopenia in adult patients with...” gsk.com ↗ |
| Filed | US (FDA) | Promacta | chronic hepatitis C virus infection | 2012-05-30 | “a supplemental New Drug Application to the US Food and Drug Administration for Promacta (eltrombopag) as a treatment for thrombocytopenia in adult patients with chronic...” ligand.com ↗ |
| Filed primary thrombocytopenia 2 milestones | |||||
| Filed | US (FDA) | PROMACTA | primary thrombocytopenia | 2007-12-20 | “GlaxoSmithKline submitted an NDA for PROMACTA(TM) (eltrombopag) for the treatment of short-term immune thrombocytopenic purpura (ITP) in” ligand.com ↗ “as a result of GSK's submission of a New Drug Application (NDA) for PROMACTA(R) (eltrombopag).” ligand.com ↗ |
| Filed | EU (EMA) | Revolade | primary thrombocytopenia | — | “The submission of eltrombopag and ofatumumab to the European Medicines Agency for regulatory review in December 2008” gsk.com ↗ “Revolade was submitted for approval in Europe in December 2008” ligand.com ↗ |
| Approved Indication not stated 2 milestones | |||||
| Approved | US (FDA) | ELTROMBOPAG | — | 2026-03-16 | fda.gov ↗ |
| Approved | EU (EMA) | Revolade | — | 2010-03-11 | europa.eu ↗ |
Trials 127 · started per year
today
EU approved 2010
US approved 2026
1
5
4
2
8
7
7
14
11
8
7
4
3
10
8
10
4
5
1
2
4
2
200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
News releases announcing trial results or a regulatory action · 58
| Date | Issuer | Release |
|---|---|---|
| 2026-01-15 | Zydus Lifesciences Limited | Regulatory Zydus receives final approval from USFDA for Eltrombopag Tablets, 12.5 mg, 25 mg, 50 mg, and 75 mg zyduslife.com ↗
Zydus Lifesciences Limited (including its subsidiaries/ affiliates, hereafter referred to as “Zydus”) has received final approval from the United States Food and Drug Administration (USFDA) for Eltrombopag Tablets, 12.5 mg, 25 mg, 50 mg, and 75 mg (USRLD: Promacta Tablets, 12.5 mg, 25 mg, 50 mg, and 75 mg). |
| 2025-12-09 | Novartis Pharmaceuticals | Results Novartis ianalumab significantly extends disease control in patients with immune thrombocytopenia with only four once-monthly doses novartis.com ↗ |
| 2025-11-25 | Novartis Pharmaceuticals | Results Novartis data underscore pioneering scientific innovation in hematology and oncology at ASH and SABCS novartis.com ↗
Primary results from VAYHIT2, a randomized, double-blind, Phase 3 trial of ianalumab plus eltrombopag versus placebo plus eltrombopag in patients with primary immune thrombocytopenia (ITP) who failed first-line corticosteroid treatment |
| 2025-08-12 | Novartis Pharmaceuticals | Results Novartis ianalumab Phase III trial meets primary endpoint in ITP, demonstrating statistically significant improvement in time to treatment failure novartis.com ↗
Novartis today announced positive top-line results from VAYHIT2, a Phase III trial evaluating ianalumab plus eltrombopag in patients with primary immune thrombocytopenia (ITP) previously treated with corticosteroids 1,2 . |
| 2018-12-02 | Novartis Pharmaceuticals | Results Real-world data show Novartis drug Revolade® improves outcomes for ITP patients compared to other second-line therapies novartis.com ↗
Revolade (eltrombopag) showed lower rate of bleeding-related episodes and similar rate of thrombotic events vs. romiplostim, rituximab and splenectomy, in a retrospective analysis of US electronic health records |
| 2018-11-16 | Novartis Pharmaceuticals | Regulatory FDA approves Novartis drug Promacta® for first-line SAA and grants Breakthrough Therapy designation for additional new indication novartis.com ↗
Basel, November 16, 2018 - Novartis announced today that the US Food and Drug Administration (FDA) has expanded the label for Promacta ® (eltrombopag) to include first-line treatment for adults and pediatric patients two years and older with SAA in combination with standard immunosuppressive therapy (IST). |
| 2018-05-30 | Novartis Pharmaceuticals | Regulatory FDA expedites review of Novartis drug Promacta® for first-line severe aplastic anemia (SAA) novartis.com ↗
Promacta receives FDA Priority Review for first-line treatment of SAA based on data showing 52% complete response rate and 85% overall response rate when added to standard immunosuppressive therapy (IST) |
| 2018-01-04 | Novartis Pharmaceuticals | Regulatory Novartis drug Promacta® receives FDA Breakthrough Therapy designation for first-line use in severe aplastic anemia (SAA) novartis.com ↗ |
| 2017-10-18 | Novartis Pharmaceuticals | Results Novartis drug Revolade® shows long-term disease control for chronic/persistent immune thrombocytopenia (ITP) novartis.com ↗
Novartis today announced long-term study results supporting the positive safety and efficacy of Revolade (eltrombopag) in adults with chronic/persistent (enrolling patients that were 6 or more months from diagnosis) immune (idiopathic) thrombocytopenia (ITP) were published online in Blood. |
| 2017-04-19 | Novartis Pharmaceuticals | Results NIH study in NEJM shows Novartis drug eltrombopag as first-line therapy with standard treatment improves responses in severe aplastic anemia novartis.com ↗
NIH study found 58% of patients with treatment-naïve severe aplastic anemia (SAA) achieved a complete response when eltrombopag was given at the initiation of and concurrently with standard immunosuppressive therapy[1] |
| 2016-11-16 | Novartis Pharmaceuticals | Results Novartis data at ASH and SABCS showcase latest innovations in development for patients with blood disorders and breast cancer novartis.com ↗
Patient-Reported Health-Related Quality of Life Improves Over Time in Patients with Chronic Immune Thrombocytopenia Receiving Long-Term Treatment with Eltrombopag |
| 2016-06-10 | Novartis Pharmaceuticals | Results Novartis highlights long-term safety data of Revolade® in adults with chronic immune thrombocytopenia, a rare blood disorder novartis.com ↗
EXTEND study provides long-term safety data for Revolade that are consistent with the findings from the pivotal Phase III RAISE study[1,2] |
| 2016-04-07 | Novartis Pharmaceuticals | Regulatory Novartis receives EU approval for Revolade® as first-in-class therapy for children aged 1 year and above with chronic ITP novartis.com ↗
Novartis announced today that the European Commission (EC) has approved Revolade ® (eltrombopag) for the treatment of pediatric (aged 1 year and above) chronic immune (idiopathic) thrombocytopenic purpura (ITP) patients who are refractory to other treatments (e.g. corticosteroids, immunoglobulins). |
| 2016-04-07 | Ligand Pharmaceuticals | Regulatory Revolade® Approved in EU as First in Class Therapy for Children Aged 1 Year and Above with Chronic ITP ligand.com ↗
EU approval of Revolade expands treatment options for pediatric patients aged 1 year and above with chronic ITP who have not responded to other therapies |
| 2015-09-02 | Novartis Pharmaceuticals | Regulatory Novartis receives EU approval for new Revolade® use as first-in-class therapy for patients with severe aplastic anemia novartis.com ↗ |
| 2015-09-02 | Ligand Pharmaceuticals | Regulatory Revolade® Receives EU Approval as First-in-Class Therapy for Patients with Severe Aplastic Anemia ligand.com ↗
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces the European Commission has approved Revolade® (eltrombopag), a Novartis product, for the treatment of adults with severe aplastic anemia (SAA) who were either refractory to prior immunosuppressive therapy or heavily pretreated and are unsuitable for hematopoietic stem cell transplant. |
| 2015-08-24 | Novartis Pharmaceuticals | Regulatory FDA expands use of Novartis drug Promacta® to include treatment of children ages 1 and older with chronic immune thrombocytopenia novartis.com ↗ |
| 2015-08-24 | Ligand Pharmaceuticals | Regulatory FDA Expands Use of Promacta® to Include Treatment of Children Ages 1 and Older with Chronic Immune Thrombocytopenia ligand.com ↗
FDA Expands Use of Promacta® to Include Treatment of Children Ages 1 and Older with Chronic Immune Thrombocytopenia |
| 2015-07-24 | Novartis Pharmaceuticals | Regulatory Novartis drug Revolade® recommended by CHMP for EU approval to treat patients with severe aplastic anemia, a serious blood disorder novartis.com ↗
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for Revolade ® (eltrombopag) |
| 2015-07-24 | Ligand Pharmaceuticals | Regulatory Revolade® Recommended by CHMP for EU Approval to Treat Patients with Severe Aplastic Anemia, a Serious Blood Disorder ligand.com ↗
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for Revolade® (eltrombopag), a Novartis product, for the treatment of adult patients with acquired severe aplastic anemia (SAA) who were either refractory to prior immunosuppressive therapy (IST) or heavily pretreated and are unsuitable for hematopoietic stem cell transplantation. |
| 2015-06-12 | Ligand Pharmaceuticals | Regulatory FDA Approves Promacta® for New Pediatric Chronic Immune Thrombocytopenia (cITP) Indication ligand.com ↗
FDA Approves Promacta® for New Pediatric Chronic Immune Thrombocytopenia (cITP) Indication |
| 2015-06-11 | Novartis Pharmaceuticals | Regulatory Novartis gains FDA approval for Promacta® providing new option for children, ages 6 and older, with chronic ITP, a rare blood disorder novartis.com ↗
Basel, June 11, 2015 - Novartis announced today that the US Food and Drug Administration (FDA) has approved Promacta ® (eltrombopag) for the treatment of children six years and older with chronic immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy. |
| 2015-02-06 | GlaxoSmithKline | Regulatory GSK announces EU regulatory submission seeking additional indication for eltrombopag (Revolade™) gsk.com ↗
GSK today announced the submission to the European Medicines Agency (EMA) of a variation to the Marketing Authorisation for eltrombopag (Revolade™), seeking an additional indication |
| 2015-02-06 | Ligand Pharmaceuticals | Regulatory Ligand Partner GlaxoSmithKline Announces EU Regulatory Submission Seeking Additional Indication for Revolade® ligand.com ↗
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that its partner GlaxoSmithKline (GSK) plc reported the submission to the European Medicines Agency (EMA) of a variation to the Marketing Authorization for eltrombopag (Revolade®), seeking an additional indication for the treatment of pediatric patients (age 1 year and above) with chronic immune (idiopathic) thrombocytopenic purpura (ITP) who have had an insufficient response to corticosteroids or immunoglobulins. |
| 2014-12-22 | GlaxoSmithKline | Regulatory GSK announces US regulatory submission seeking additional indication for eltrombopag (Promacta™) gsk.com ↗
GSK today announced the submission of a supplemental New Drug Application (sNDA) to the US Food and Drug Administration for eltrombopag (Promacta™), seeking an additional indication in paediatric patients six years and older with chronic immune (idiopathic) thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy. |
| 2014-12-22 | Ligand Pharmaceuticals | Regulatory Ligand Partner GlaxoSmithKline Announces US Regulatory Submission Seeking Additional Indication for Promacta® ligand.com ↗
the submission of a supplemental New Drug Application (sNDA) to the US Food and Drug Administration for eltrombopag (Promacta) |
| 2014-11-12 | GlaxoSmithKline | Regulatory GSK announces EU regulatory submission seeking additional indication for eltrombopag (Revolade™) (1) gsk.com ↗
GSK today announced the submission to the European Medicines Agency (EMA) of a variation to the Marketing Authorisation for eltrombopag (Revolade™), seeking an additional indication |
| 2014-11-12 | Ligand Pharmaceuticals | Regulatory Ligand Partner GlaxoSmithKline Announces EU Regulatory Submission for Severe Aplastic Anemia Indication for Revolade™ (eltrombopag) ligand.com ↗
Ligand Partner GlaxoSmithKline Announces EU Regulatory Submission for Severe Aplastic Anemia Indication for Revolade™ (eltrombopag) |
| 2014-08-27 | Ligand Pharmaceuticals | Regulatory Ligand Partner GlaxoSmithKline Receives U.S. FDA Approval for Promacta®/Revolade™ For Use in Patients with Severe Aplastic Anemia ligand.com ↗
Ligand Partner GlaxoSmithKline Receives U.S. FDA Approval for Promacta®/Revolade™ For Use in Patients with Severe Aplastic Anemia |
| 2014-08-26 | GlaxoSmithKline | Regulatory GSK's Promacta® (eltrombopag) receives FDA approval of an additional indication gsk.com ↗ |
| 2014-06-13 | GlaxoSmithKline | Results GSK announces results of Phase III PETIT2 study of eltrombopag (Promacta™/Revolade™) in paediatric patients with chronic immune thrombocytopenia gsk.com ↗
Issued: London UK GlaxoSmithKline (GSK) plc today announced the results from the Phase III PETIT2 study evaluating the efficacy of eltrombopag vs. placebo in paediatric patients with chronic immune (idiopathic) thrombocytopenic purpura (cITP). |
| 2014-06-13 | Ligand Pharmaceuticals | Results Ligand Partner GSK Announces Results of Phase 3 PETIT2 Study of Eltrombopag (Promacta™/Revolade™) in Pediatric Patients with Chronic Immune Thrombocytopenia ligand.com ↗
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that its partner, GlaxoSmithKline (GSK) plc, presented the results from the Phase 3 PETIT2 study evaluating the efficacy of eltrombopag vs. placebo in pediatric patients with chronic immune (idiopathic) thrombocytopenic purpura (cITP). |
| 2014-04-30 | Ligand Pharmaceuticals | Regulatory Ligand Partner GlaxoSmithKline Gains Priority Review Designation for Promacta™/Revolade™ for Severe Aplastic Anemia ligand.com ↗ |
| 2014-02-28 | GlaxoSmithKline | Regulatory GSK announces submission to U.S. regulatory authorities for Promacta™ (eltrombopag) for severe aplastic anaemia gsk.com ↗ |
| 2014-02-28 | Ligand Pharmaceuticals | Regulatory Ligand Partner GlaxoSmithKline Submits U.S. Regulatory Application for Promacta® (eltrombopag) for Severe Aplastic Anaemia ligand.com ↗
Ligand Partner GlaxoSmithKline Submits U.S. Regulatory Application for Promacta® (eltrombopag) for Severe Aplastic Anaemia |
| 2014-02-03 | GlaxoSmithKline | Regulatory GSK gains FDA Breakthrough Therapy designation for Promacta®/Revolade® (eltrombopag) for severe aplastic anaemia gsk.com ↗ |
| 2014-02-03 | Ligand Pharmaceuticals | Regulatory Ligand Partner GlaxoSmithKline Gains FDA Breakthrough Therapy Designation for Promacta®/Revolade® for Severe Aplastic Anemia ligand.com ↗ |
| 2013-09-24 | GlaxoSmithKline | Regulatory GSK receives marketing authorisation from the European Commission for additional Revolade™ gsk.com ↗ |
| 2013-09-24 | Ligand Pharmaceuticals | Regulatory Ligand Partner GSK Receives Marketing Authorization from the European Commission for Additional Revolade™ (Eltrombopag) Indication as the First Approved Treatment for Chronic Hepatitis C-Associated Thrombocytopenia ligand.com ↗
We are extremely pleased with the decision of the European Commission, and eagerly await the launch of Revolade in the European Union for this indication. |
| 2013-07-26 | GlaxoSmithKline | Regulatory GSK receives positive CHMP opinion for REVOLADE in thrombocytopenia associated with chronic hepatitis C infection gsk.com ↗ |
| 2013-07-26 | Ligand Pharmaceuticals | Regulatory Ligand Partner GlaxoSmithKline Receives Positive CHMP Opinion for REVOLADE™ in Thrombocytopenia Associated with Chronic Hepatitis C Infection ligand.com ↗
GlaxoSmithKline (NYSE: GSK) announced that today, the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending marketing authorization for GSK’s REVOLADE™ (eltrombopag) as a treatment for low platelet counts (thrombocytopenia) in adult patients with chronic hepatitis C infection, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy. |
| 2012-11-19 | Ligand Pharmaceuticals | Regulatory Ligand Partner GlaxoSmithKline Receives FDA Approval for New Indication for PROMACTA® (eltrombopag) ligand.com ↗
Ligand Partner GlaxoSmithKline Receives FDA Approval for New Indication for PROMACTA® (eltrombopag) |
| 2012-07-25 | Ligand Pharmaceuticals | Regulatory Ligand Partner GlaxoSmithKline Announces Priority Review for Supplemental New Drug Application for Promacta® for the Treatment of Thrombocytopenia in Adult Patients with Chronic Hepatitis C Infection ligand.com ↗
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that its partner GlaxoSmithKline (NYSE: GSK) has been granted priority review from the US Food and Drug Administration for the supplemental new drug application for Promacta® to treat thrombocytopenia in adult patients with chronic hepatitis C virus (HCV) infection. |
| 2012-05-30 | GlaxoSmithKline | Regulatory Regulatory Update – GSK announces submissions in the EU & US for new indications for Promacta®/Revolade® gsk.com ↗
GlaxoSmithKline plc announced today that it has submitted regulatory applications in the European Union and United States related to eltrombopag (Promacta®/ Revolade® ) |
| 2012-05-30 | Ligand Pharmaceuticals | Regulatory Ligand Partner GlaxoSmithKline Submits US and European Regulatory Applications for use of PROMACTA/REVOLADE to Increase Platelet Counts in Patients with Hepatitis C ligand.com ↗
Ligand Partner GlaxoSmithKline Submits US and European Regulatory Applications for use of PROMACTA/REVOLADE to Increase Platelet Counts in Patients with Hepatitis C |
| 2011-11-07 | GlaxoSmithKline | Results GSK presents phase III results for eltrombopag in hepatitis C virus related thrombocytopenia gsk.com ↗
The ENABLE 2 trial met its primary endpoint of improved SVR, with 19% of eltrombopag patients and 13% of placebo patients achieving SVR (p=0.0202). |
| 2011-07-26 | Ligand Pharmaceuticals | Results Ligand Partner GlaxoSmithKline Receives Positive Data from Promacta(R) PIII ENABLE1 Study in Hepatitis C-Related Thrombocytopenia ligand.com ↗
Ligand Partner GlaxoSmithKline Receives Positive Data from Promacta(R) PIII ENABLE1 Study in Hepatitis C-Related Thrombocytopenia |
| 2010-11-02 | Ligand Pharmaceuticals | Regulatory Ligand Announces Approval for Revolade(R) in Japan ligand.com ↗
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced its partner GlaxoSmithKline (NYSE:GSK) was granted approval from the Japanese Ministry of Health, Labour and Welfare for Revolade(R) (eltrombopag) for the treatment of the blood disorder, chronic idiopathic thrombocytopenic purpura (ITP). |
| 2010-10-28 | GlaxoSmithKline | Regulatory GlaxoSmithKline receives approval in Japan for two medicines: Revolade and Xyzal gsk.com ↗ |
| 2010-03-12 | Ligand Pharmaceuticals | Regulatory Ligand Announces Approval for Revolade(R) in Europe ligand.com ↗
Ligand Announces Approval for Revolade(R) in Europe |
| 2010-03-11 | GlaxoSmithKline | Regulatory GlaxoSmithKline receives marketing authorisation in the EU for Revolade® (eltrombopag) gsk.com ↗
GlaxoSmithKline (GSK) confirmed today that the European Commission (EC) has granted marketing authorisation for Revolade ® (eltrombopag) for the oral treatment of thrombocytopenia (reduced platelet count) in adults with the blood disorder chronic immune (idiopathic) thrombocytopenic purpura (ITP). |
| 2009-12-18 | Ligand Pharmaceuticals | Regulatory Ligand Announces Positive Regulatory Opinion in Europe for Revolade for Chronic Immune Thrombocytopenic Purpura ligand.com ↗
Ligand Announces Positive Regulatory Opinion in Europe for Revolade for Chronic Immune Thrombocytopenic Purpura |
| 2009-12-17 | GlaxoSmithKline | Regulatory Revolade (eltrombopag) receives positive opinion in Europe for chronic immune thrombocytopenic purpura gsk.com ↗ |
| 2009-06-04 | GlaxoSmithKline | Results Positive results with Revolade™ and Arzerra™ for difficult-to-treat blood disorders gsk.com ↗
New data from two long-term studies (RAISE – 197 patients and EXTEND – 144 patients) show that patients treated with eltrombopag experienced significant elevations in platelet counts, as well as a reduction in bleeding and bruising, compared with placebo. |
| 2008-11-21 | Ligand Pharmaceuticals | Regulatory Ligand Collaborator GlaxoSmithKline Receives FDA Approval for PROMACTA(R) ligand.com ↗
Ligand Collaborator GlaxoSmithKline Receives FDA Approval for PROMACTA(R) |
| 2008-06-20 | Ligand Pharmaceuticals | Regulatory Ligand Partner GlaxoSmithKline Receives FDA Extended Priority Review for PROMACTA(R) NDA ligand.com ↗ |
| 2008-03-03 | Ligand Pharmaceuticals | Regulatory Ligand Partner GlaxoSmithKline Receives FDA Acceptance and Granted Priority Review for PROMACTA(R) NDA ligand.com ↗
Ligand Partner GlaxoSmithKline Receives FDA Acceptance and Granted Priority Review for PROMACTA(R) NDA |
| 2007-12-20 | Ligand Pharmaceuticals | Regulatory Ligand Earns $1 Million Milestone Payment as GlaxoSmithKline Submits New Drug Application for PROMACTA(R) (eltrombopag) ligand.com ↗
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) (the Company or Ligand) today announced that it has earned from GlaxoSmithKline (NYSE:GSK) (GSK) a milestone payment of $1 million as a result of GSK's submission of a New Drug Application (NDA) for PROMACTA(R) (eltrombopag). |
All press releases naming this drug 63 releases
Evidence & citations 15 cited values
Every value below carries the sentence it was read from. 157 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Eltrombopag | “Eltrombopag initial dose: 25 mg orally once a day, may increase to up to 75 mg/day, when platelet count ≤ 30 × 109/L; Avatrombopag initial dose: 20 mg orally once a day, may...” NCT05907499 ↗149“The investigators developed, in this study, a standardized procedure to discontinue Eltrombopag and Romiplostim, wherein the dose will be slowly tapered to limit the risk of bleeding.” NCT03119974 ↗ “This study aims to identify patient characteristics that predict effective eltrombopag dosage for the treatment of Hepatitis C virus (HCV)-related thrombocytopenia.” PMID 26173631 ↗ Oct 2015 “Hetrombopag is given at an initial dose of 7.5 mg once daily for 14 days; eltrombopag is given at an initial dose of 75 mg once daily for 14 days” NCT07669675 ↗ “Thrombopoietin mimetic (Eltrombopag) was firstly FDA approved for treatment of immune thrombocytopenic purpura.” NCT03896971 ↗ “Three TPO-RAs could be used in this study, including eltrombopag, hetrombopag and avatrombopag.” NCT05718856 ↗ “Eltrombopag (Promacta ), an oral 2nd generation small molecule TPO-agonist” NCT01623167 ↗ “The starting dose of eltrombopag is 50-75mg once daily.” NCT04915482 ↗ “Eltrombopag: initial dose 50mg/d, maximum dose 150mg/d” NCT07523009 ↗ “Eltrombopag 50mg/d, increased by 25mg every two weeks” NCT07558434 ↗ “eltrombopag” NCT07421167 ↗ |
| Known as | ELT | “Eltrombopag (ELT)” NCT01957176 ↗ |
| Known as | ELTR | “We compared the efficacy and safety of eltrombopag (ELTR) combined with immunosuppressive therapy (IST) and IST alone in treatment-naïve children with severe (SAA) and very...” PMID 35446936 ↗ Mar 2023 |
| Known as | Eltrombopag (EPAG) | “Eltrombopag (EPAG)” NCT07558434 ↗ |
| Known as | Eltrombopag Olamine | “Eltrombopag olamine (SB-497115-GR) is an orally bioavailable, small molecule thrombopoietin receptor agonist that may be beneficial in medical disorders associated with...” NCT02158936 ↗6“Eltrombopag tablets will be white, round film coated tablets containing eltrombopag olamine equivalent to 12.5 mg, 25 mg, 50 mg and 75 mg of eltrombopag.” NCT02201290 ↗ “An Open-label Repeat Dosing Study of Eltrombopag Olamine (SB-497115-GR) in Adult Subjects, With Chronic Idiopathic Thrombocytopenic Purpura (ITP)” NCT00424177 ↗ “eltrombopag olamine (SB-497115-GR), a thrombopoietin receptor agonist” NCT00370331 ↗ “Drug: Eltrombopag Olamine” NCT01428635 ↗ “Drug: Eltrombopag olamine” NCT01147809 ↗ “Drug: Eltrombopag olamine” NCT01098487 ↗ |
| Known as | EPAG | “Eltrombopag (EPAG) received approval from the US Food and Drug Administration for the treatment of refractory severe aplastic anemia (rSAA) based on treatment of 43 patients...” PMID 30992268 ↗ Apr 20193“Eltrombopag (EPAG), a small molecule thrombopoietin mimetic, has previously been shown to result in durable multi-lineage hematologic responses with low toxicity in patients...” PMID 32330244 ↗ Apr 2020 “eltrombopag (EPAG)/hetrombopag (HPAG)” NCT07523009 ↗ “Eltrombopag (EPAG)” NCT06630221 ↗ |
| Known as | PROMACTA | “This is a Phase IV study to evaluate eltrombopag concentrations in breast milk of nursing mothers taking marketed eltrombopag (PROMACTA®).” NCT01055600 ↗ |
| Known as | Revolade | “An Open-label Single-dose Pharmacokinetic Study of an Oral Formulation in Tablets Containing Eltrombopag 50 mg (Revolade, Glaxosmithkline Mexico, S.A. De C.V.) in Healthy...” NCT02254434 ↗6“Eltrombopag (Revolade) is a thrombopoietin receptor agonist indicated for the treatment of adult patients with ITP relapsed/refractory to splenectomy” NCT01791101 ↗ “Administration of Eltrombopag (Revolade®), 50 mg PO, from day 5-140.” NCT04812483 ↗ “Drug: Eltrombopag/Revolade” NCT02928419 ↗ “Eltrombopag (Revolade®)” NCT06607367 ↗ “Revolade (eltrombopag)” NCT01488565 ↗ “Eltrombopag/Revolade” NCT02912208 ↗ |
| Known as | Revolade (eltrombopag) | “Revolade (eltrombopag)” NCT01500538 ↗1“Revolade (eltrombopag)” NCT01488565 ↗ |
| Known as | SB-497115 | “SB-497115 (Oral Thrombopoietin Receptor Agonist) Versus Placebo In Adult Cancer Patients Receiving Chemotherapy” NCT00102726 ↗ |
| Known as | SB-497115-GR | “Eltrombopag olamine (SB-497115-GR) is an orally bioavailable, small molecule thrombopoietin receptor agonist that may be beneficial in medical disorders associated with...” NCT02158936 ↗6“A Longitudinal 2-year Bone Marrow Study of Eltrombopag Olamine (SB-497115-GR) in Previously Treated Adults, With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP)” NCT01098487 ↗ “An Open-label Repeat Dosing Study of Eltrombopag Olamine (SB-497115-GR) in Adult Subjects, With Chronic Idiopathic Thrombocytopenic Purpura (ITP)” NCT00424177 ↗ “Eltrombopag was provided as white round film-coated tablets containing 12.5 mg or 25 mg of eltrombopag free acid (SB-497115-GR, eltrombopag).” NCT02404025 ↗ “White, round, film-coated tablets containing 12.5 mg of eltrombopag free acid (SB-497115-GR, eltrombopag) in each tablet” NCT02148133 ↗ “eltrombopag olamine (SB-497115-GR), a thrombopoietin receptor agonist” NCT00370331 ↗ “Eltrombopag (SB-497115-GR)” NCT01147809 ↗ |
| Action | Activate | “activates the thrombopoietin receptor” NCT00102726 ↗ |
| Modality | Small molecule | “eltrombopag, an oral, nonpeptide, thrombopoietin receptor agonist” PMID 23497336 ↗ Mar 2013 |
| Route | Oral | “administered orally daily on days 2 through 11 for each 21-day cycle” NCT00102726 ↗ |
| Target | MPL | “Thrombopoietin Receptor (MPL) Agonist Eltrombopag.” NCT00888901 ↗ |